110859-47-7

Usage

Uses

Used in Pharmaceutical Research:
(4-Benzyl-1,4-oxazinan-2-yl)methylamine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure, which includes a benzyl group and a methylamine group, may contribute to the development of new drugs with specific therapeutic properties.
Used in Chemical Research:
In the field of chemical research, (4-Benzyl-1,4-oxazinan-2-yl)methylamine serves as a valuable compound for studying the properties and reactions of oxazinanamines. Its potential reactivity and interactions with other molecules can provide insights into the development of new chemical processes and materials.
Used in Drug Development:
(4-Benzyl-1,4-oxazinan-2-yl)methylamine is used as a potential candidate for drug development, given its unique structural features. Its benzyl and methylamine groups may offer opportunities for the design of novel therapeutic agents with specific pharmacological activities, such as targeting particular receptors or enzymes in the body.
Used in Organic Synthesis:
In organic synthesis, (4-Benzyl-1,4-oxazinan-2-yl)methylamine can be employed as a building block or a reactant in the preparation of more complex organic molecules. Its oxazinane ring and functional groups may facilitate the formation of new chemical entities with diverse applications.
Note: The specific applications mentioned above are hypothetical and based on the general properties of the compound. Further research and experimentation would be required to confirm the actual uses and benefits of (4-Benzyl-1,4-oxazinan-2-yl)methylamine in these areas.

InChI:InChI=1/C12H18N2O/c13-8-12-10-14(6-7-15-12)9-11-4-2-1-3-5-11/h1-5,12H,6-10,13H2

Upstream product

• 112913-96-9 2-(N-acetylaminomethyl)-4-benzylmorpholine 
• 112913-97-0 2-(azidomethyl)-4-benzylmorpholine 
• 79-37-8 oxalyl dichloride 
• 259538-37-9 4-benzyl-(2R)-5-oxo-2-morpholinecarboxylic acid 
• 100-52-7 benzaldehyde 
• 1030837-46-7 3-(benzyl(2-hydroxyethyl)amino)-2-chloro-propanenitrile 
• 104-63-2 N-Benzylethanolamine 
• 147767-51-9 4-benzyl-2-cyanomorpholine 
• 40987-25-5 N-benzyl-2-chloromethylmorpholine 
• 110859-48-8 N-[(4-benzyl-2-morpholinyl)methyl]phthalimide 

Downstream Products

• 112885-23-1 4-amino-N-<(4-benzyl-2-morpholinyl)methyl>-5-chloro-2-methoxybenzamide 
• 126645-56-5 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-2-methoxy-benzamide 
• 126645-61-2 N-(4-Benzyl-morpholin-2-ylmethyl)-2,3,4,5,6-pentafluoro-benzamide 
• 112885-48-0 4-Acetylamino-N-(4-benzyl-morpholin-2-ylmethyl)-2-methoxy-benzamide 
• 112887-18-0 N-(4-Benzyl-morpholin-2-ylmethyl)-2-chloro-5-sulfamoyl-benzamide 
• 112885-62-8 4-Acetylamino-N-(4-benzyl-morpholin-2-ylmethyl)-5-chloro-2-hydroxy-benzamide 
• 112887-21-5 N-(4-Benzyl-morpholin-2-ylmethyl)-2-methoxy-5-sulfamoyl-benzamide 
• 126645-63-4 N-(4-Benzyl-morpholin-2-ylmethyl)-2,3-dimethoxy-benzamide 
• 112885-49-1 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-4-dimethylamino-2-hydroxy-benzamide 
• 112887-22-6 N-<(4-benzyl-2-morpholinyl)methyl>-4-chloro-2-methoxy-5-nitrobenzamide 
• 126645-57-6 4-Amino-N-(4-benzyl-morpholin-2-ylmethyl)-3-chloro-benzamide 
• 112885-57-1 4-Amino-N-(4-benzyl-morpholin-2-ylmethyl)-5-bromo-2-methoxy-benzamide 
• 126645-58-7 N-(4-Benzyl-morpholin-2-ylmethyl)-3,5-dichloro-4-dimethylamino-2-hydroxy-benzamide 
• 112885-53-7 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-4-diethylamino-2-methoxy-benzamide 

Relevant academic research and scientific papers

INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS

The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes

PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development.

A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to a novel compound, or a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) comprising the same. The invention provides a compound, which has excellent activity and solubility and is more efficiently formulated and delivered, and a pharmaceutical composition for human-11-beta-hydroxysteroid dehydrogenase type 1 comprising the same.

HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS

Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials .

NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY

The invention relates to novel antibacterial compounds of formula (I).

ANTITHROMBOTIC AGENTS

Compounds of formula (I): Are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisa

Antithrombotic agents

Compounds of formula (I) : are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilis

Pyrimidine derivatives

Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula STR1 wherein X is O or NR5, Y is O, S or NR5 wherein R5 is a hydrogen atom, a C1 -C6 alkyl group or the like; R1 and R2 may be the same or different and each is a hydrogen atom, a C1 -C6 alkyl group or the like; R3 is CN, or COOR6 wherein R6 is a C1 -C6 alkyl group, a C3 -C6 cycloalkyl group, an aryl group or the like; R4 is --SR7 or --NR8 R9 wherein R7 is a C1 -C6 alkyl group; R8 is a C1 -C6 alkyl group or the like; R9 is a hydrogen atom, a C1 -C6 alkyl group or the like, or R8 and R9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) STR2 wherein R10 represents a C1 -C6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.